Table 1.
Adequacy rate of EUS-TA samples for NGS in pancreatic solid mass.
| Author (Year) | Study Type | No. of Patients | Type of Tumor | Biopsy Type | Needle | Adequacy Rate for NGS | P-Value | Required Tumor Fraction | Genes Targeted | Frequency of Genomic Alterations |
|---|---|---|---|---|---|---|---|---|---|---|
| Elhanafi S, et al. (2018) | Retrospective cohort study | 167 | PDAC | EUS-FNA/B | 70.1% | ≥10% | Custom panel (47 genes) | KRAS (88%), TP53 (68%), SMAD4 (16%) | ||
| 145 | EUS-FNA | EUSN-3 (22-gauge) | 66.9% | 0.02 | ||||||
| 22 | EUS-FNB | SharkCore/ProCore (22-gauge) | 90.9% | |||||||
| Larson BK, et al. (2018) | Retrospective study | 61 | Pancreatic exocrine malignancy | EUS-FNA/B | 67.2% | ≥20% | FoundationOne (315 genes) | NA | ||
| 7 | EUS-FNA | NA | 42.9% | 0.1494 | ||||||
| 54 | EUS-FNB | SharkCore/ProCore | 70.4% | |||||||
| Gleeson FC, et al. (2017) | Retrospective study | 156 | PanNET | EUS-FNA | NA | 58% | ≥20% | Custom GeneRead DNAseq Targeted Panel V2 (15 genes) | MEN1 (42%), DAXX (11%), ATRX (10%), TSC2 (8%) | |
| Young G, et al. (2013) | Retrospective study | 23 | PDAC, Mucinous adenocarcinoma, adenocarcinoma NOS, PanNET | EUS-FNA | NA | 100% | ≥20% | Custom panel (287 genes) | KRAS (78%), TP53 (74%), CDKN2A/B (35%), SMAD4 (17%), PTEN (13%) | |
| Gleeson FC, et al. (2016) | Retrospective study | 47 | PDAC, Ampullary adenocarcinoma, IPMN, Lynch syndrome associated PDAC | EUS-FNA | NA | 61.7% | ≥20% | Human Comprehensive Cancer GeneRead DNAseq Targeted Panel V2 (160 genes) | KRAS (93.1%), TP53 (72.4%), SMAD4 (31%), GNAS (10.3%) |
NGS, next generation sequencing; PDAC, pancreatic ductal adenocarcinoma; NOS, not otherwise specified; PanNET, pancreatic neuroendocrine tumor; IPMN, intraductal papillary mucinous neoplasm; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; EUS-FNB, endoscopic ultrasound-guided fine needle biopsy; NA, not available.